<![CDATA[Det siger de hos Jim]]>Eli Lilly's next-generation weight-loss injectable retatrutide helped obesity patients lose 28% of their body weight on average in a late-stage trial. This more powerful drug may not be for everybody, but it helps Lilly build out a broader GLP-1 portfolio alongside injectable Zepbound and pill Foundayo. It's about options. Clear leader over Novo Nordisk.

Mon det passer at Novo er "second"

]]>https://dev.proinvestor.com/forum/topic/448248/det-siger-de-hos-jimRSS for NodeTue, 09 Jun 2026 22:29:07 GMTThu, 21 May 2026 11:23:19 GMT60<![CDATA[Reply to Det siger de hos Jim on Thu, 21 May 2026 14:52:16 GMT]]>Det handler mindre om procenter, men derimod om bivirkninger, der kan forhindre brugere i at benytte et produkt over en længere periode...

]]>https://dev.proinvestor.com/forum/post/9497707https://dev.proinvestor.com/forum/post/9497707Thu, 21 May 2026 14:52:16 GMT